1) NPO法人日本せきずい基金.http://www.jscf.org/(2024年2月26日アクセス)
2) 柴崎啓一.全国脊髄損傷登録統計 2002年1月-12月.日脊障医誌2005;18:271-4.
3) Osaka M, Honmou O, Murakami T, et al. Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome. Brain Res 2010;1343:226-35.
4) Honmou O, Houkin K, Matsunaga T, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011;134(Pt 6):1790-807.
5) Honmou O, Onodera R, Sasaki M, et al. Mesenchymal stem cells:therapeutic outlook for stroke. Trends Mol Med 2012;18(5):292-7.
6) Akiyama Y, Radtke C, Honmou O, et al. Remyelination of the spinal cord following intravenous delivery of bone marrow cells. Glia 2002;39(3):229-36.
7) Morita T, Sasaki M, Kataoka-Sasaki Y, et al . Intravenous infusion of mesenchymal stem cells promotes functional recovery in a model of chronic spinal cord injury. Neuroscience 2016;335:221-31.
8) Oshigiri T, Sasaki T, Sasaki M , et al. Intravenous infusion of mesenchymal stem cells alters motor cortex gene expression in a rat model of acute spinal cord injury. J Neurotrauma 2019;36(3):411-20.
9) Kurihara K, Sasaki M, Nagahama H, et al. Repeated intravenous infusion of mesenchymal stem cells enhances recovery of motor function in a rat model with chronic spinal cord injury. Brain Res 2023;1817:148484. doi:10.1016/j.brainres.2023.148484.
10) Hirota R, Sasaki M, Honmou O, et al. Mesenchymal stem cell transplantation for spinal cord injury:current status and prospects. Spine Surg Relat Res 2023;7(4):319-26.